相关实验视频

Updated: Jun 11, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

糖蛋白IIb-IIIa抑制剂在ST段升高心肌梗塞初级血管整形中的当前和未来作用

Giuseppe De Luca^1,2, Ashley Verburg³, Arnoud Van't Hof^4,5

¹Division of Cardiology, Polyclinic G. Martino, University of Messina, 98122 Messina, Italy.

|September 28, 2024

概括

糖蛋白 (GP) IIb-IIIa抑制剂改善了急性心肌梗塞患者,特别是高风险患者的治疗结果. 早期管理,甚至在医院前,是降低死亡率和改善再输血的关键.

科学领域:

心脏病学心脏病学
药理学药理学是指药理学的学科.
紧急医疗紧急医疗

背景情况:

急性心肌梗塞 (AMI) 仍然是高收入国家死亡的主要原因.
尽管在机械再注血方面取得了进展,但不良结果和静脉栓塞仍然存在.
目前的口服抗血小板疗法已延迟发病,需要改进早期治疗策略.

研究的目的:

评估糖蛋白 (GP) IIb-IIIa抑制剂在改善AMI患者临床结果方面的疗效.
为了确定GP IIb-IIIa抑制剂的最佳时间和患者群体.
探索像扎隆菲班这样的新药在医院前使用的潜力.

主要方法:

对AMI治疗中的GP IIb-IIIa抑制剂现有证据的审查.
影响早期血栓组成和心肌活力的因素分析.
考虑医院前和急诊室的管理策略.
在早期干预中评估沙隆菲班的药物动力学概况.

主要成果:

GP IIb-IIIa抑制剂在降低死亡率方面具有显著的益处,特别是在高风险患者中.
早期服用 (症状出现后3小时内) 与更好的结果有关.
新型药物,如扎隆菲班提供快速发病和短持续时间,适合医院前设置.
预计CELEBRATE试验将提供有关前期治疗益处的进一步数据.

结论:

GP IIb-IIIa抑制剂是AMI的有价值的辅助疗法,特别是在早期和高危人群中使用时.
应强烈考虑在医院前或即时急诊室给药GP IIb-IIIa抑制剂.
未来的研究和试验旨在优化再输注策略,以最大限度地减少心肌损伤并改善存活率.

关键词:

这是GPIIb/IIIa抑制剂.这就是为什么我们会用声音来表达.初级血管造形术的第一步.

更多相关视频

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Acute Coronary Syndrome IV: Interprofessional Care

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

Acute Coronary Syndrome II: Pathophysiology and clinical manifestations

Acute Coronary Syndrome II: Pathophysiology and clinical manifestations

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...